news
Potential target found for CDKL5 deficiency disorder
Using phosphoproteomics, the calcium channel Cav2.3 was found as a target to treat a type of genetic epilepsy, CDKL5 deficiency disorder.
List view / Grid view
MSD
news
Novel compound to kill malaria parasites developed by researchers
A collaborative team has developed a compound called WM382, which targets two crucial enzymes in the malaria parasite, effectively killing it.
news
ELRIG Drug Discovery 2019: looking back to the future
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
news
Collaboration to discover MND treatments announced
MSD and the Francis Crick Institute will work together on a project to identify disease targets for motor neuron disease.
news
Genmab appoints Judith Klimovsky as Chief Development Officer
The biotechnology company Genmab announced today the appointment of Judith Klimovsky, MD, as Executive Vice President and Chief Development Officer.
news
Ablynx extends ion channel research collaboration with MSD to develop nanobodies
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The extension agreement will trigger a €1 million payment to Ablynx, and MSD will extend their funding of the research collaboration to September 2018...
news
Chronos Therapeutics appoints new VPs for MS and PTSD research
4 August 2016 | By Niamh Marriott, Digital Content Producer
Chronos Therapeutics, a biotech company researching ageing diseases, brain and nervous system disorders, have announced the appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl, as Vice Presidents of Pre-Clinical Development...
news
A*STAR and MSD team up to advance peptide therapeutics
19 July 2016 | By Niamh Louise Marriott
A*STAR and MSD have formed a two year collaboration aimed at improving cellular delivery of macrocyclic peptides...
news
MSD and Moderna to develop personalised cancer vaccines
29 June 2016 | By Victoria White, Digital Content Producer
Moderna and MSD will develop personalised cancer vaccines that utilise Moderna’s mRNA vaccine technology to encode a patient’s specific neoantigens...
news
AbCellera and MSD enter antibody collaboration
28 January 2016 | By Victoria White
Under the agreement, AbCellera will apply its high-throughput antibody discovery platform to identify antibodies that specifically modulate target function...
news
An interview with Elaine Pinheiro, Principal Scientist at MSD, speaker at the Advances in Immuno-oncology Congress, 12-13 May 2016, London, UK
13 January 2016 | By Oxford Global
Ahead of the Advances in Immuno-oncology Congress, we spoke to Elaine Pinheiro, Principal Scientist at MSD about her group’s work and where the industry is moving at the moment...
news
MSD acquires drug discovery company IOmet
12 January 2016 | By Victoria White
The acquisition includes IOmet's comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors...
news
Complix and MSD team up for cell-penetrating alphabodies
6 January 2016 | By Victoria White
Complix will use its proprietary Alphabody platform to deliver cell-penetrating alphabodies against up to two intracellular cancer targets of interest to MSD...
news
Ablynx’s nanobody construct achieves proof-of-concept in tumour model
15 October 2015 | By Victoria White
The nanobody construct binds to two different immune modulators, proteins believed to be targets for the development of important cancer immunotherapies...
news
BioMed X and Merck Serono extend collaboration
23 July 2015 | By Victoria White
BioMed X Innovation Centre has extended its collaboration with Merck Serono, the biopharmaceuticals business of Merck, on new approaches for cancer therapy...